Ishara Investments LP Makes New Investment in Immatics N.V. $IMTX

Ishara Investments LP bought a new position in shares of Immatics N.V. (NASDAQ:IMTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 80,000 shares of the company’s stock, valued at approximately $840,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bank of America Corp DE grew its holdings in shares of Immatics by 166.0% during the 4th quarter. Bank of America Corp DE now owns 3,575 shares of the company’s stock worth $25,000 after acquiring an additional 2,231 shares during the period. Quarry LP purchased a new position in shares of Immatics during the 4th quarter worth approximately $84,000. Insigneo Advisory Services LLC purchased a new position in shares of Immatics during the 3rd quarter worth approximately $103,000. Engineers Gate Manager LP purchased a new position in shares of Immatics during the 2nd quarter worth approximately $124,000. Finally, Fox Run Management L.L.C. purchased a new position in shares of Immatics during the 4th quarter worth approximately $129,000. Hedge funds and other institutional investors own 64.41% of the company’s stock.

Immatics Trading Up 4.7%

Shares of IMTX opened at $9.52 on Thursday. The business’s fifty day simple moving average is $10.72 and its two-hundred day simple moving average is $10.22. Immatics N.V. has a 12 month low of $5.05 and a 12 month high of $12.41. The company has a market cap of $1.28 billion, a price-to-earnings ratio of -4.78 and a beta of 1.30.

Immatics (NASDAQ:IMTX) last issued its earnings results on Tuesday, May 12th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.08). Immatics had a negative net margin of 572.35% and a negative return on equity of 47.36%. The business had revenue of $8.81 million for the quarter, compared to analysts’ expectations of $9.79 million. As a group, research analysts forecast that Immatics N.V. will post -1.67 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. TD Cowen started coverage on Immatics in a report on Tuesday, April 28th. They set a “buy” rating on the stock. Jefferies Financial Group started coverage on Immatics in a research note on Monday, March 16th. They issued a “buy” rating and a $18.00 price target on the stock. Wall Street Zen downgraded Immatics from a “hold” rating to a “sell” rating in a research note on Saturday, May 2nd. Weiss Ratings restated a “sell (d)” rating on shares of Immatics in a research note on Tuesday, June 9th. Finally, Chardan Capital restated a “buy” rating and issued a $25.00 price target on shares of Immatics in a research note on Tuesday, May 19th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.80.

About Immatics

Immatics N.V. (NASDAQ: IMTX) is a clinical-stage biotechnology company dedicated to the development of T cell receptor (TCR)-based immunotherapies for solid tumors. The company leverages its proprietary discovery and engineering platforms to identify tumor-specific peptide targets and develop therapies that harness the power of a patient’s immune system. Immatics’ approach aims to generate durable responses by guiding T cells to recognize and kill cancer cells with high precision.

At the core of Immatics’ technology suite is the XPRESIDENT® platform, which mines the cancer peptidome to uncover novel tumor antigens naturally presented on the surface of cancer cells.